Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
María C. Carrillo(Brigham and Women's Hospital), Reisa A. Sperling(Harvard University), Dean M. Hartley(Autism Speaks), Howard Feldman(University of British Columbia), Ronald C. Petersen(Mayo Clinic in Arizona), Veronika Logovinsky(Eisai (United States)), Eric Siemers(Eli Lilly (United States)), J. Michael Ryan(Novartis (United States)), Ara S. Khachaturian(Prevent Alzheimer’s Disease 2020), Susan Abushakra(Framingham State University), H. Robert Brashear(Brigham and Women's Hospital)
Cited by 122
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment as a diagnostic entity
|Journal of Internal Medicine|2004|7.8k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k